Identifying GBP2 and HCK as novel therapeutic targets highlights that specific immune‐mediated mechanisms drive endometriosis, bringing our attention to the immunological aspects of the disease and paving the way for more targeted, effective treatment strategies. Here, GBP2 is linked to endometriosis.